Is it worth buying Revolution Medicines stock at a price of $47.14? If this question is on your mind, make sure to check out the fundamentals of this Biotechnology Mid-Cap company:
-
Revolution Medicines has logged a 135.5% 52 week change, compared to 39.8% for the S&P 500
-
RVMD has an average analyst rating of buy and is -21.54% away from its mean target price of $60.08 per share
-
Its trailing earnings per share (EPS) is $-3.72, which brings its trailing Price to Earnings (P/E) ratio to -12.7. The Health Care sector's average P/E ratio is 26.07
-
The company's forward earnings per share (EPS) is $-3.81 and its forward P/E ratio is -12.4
-
The company has a Price to Book (P/B) ratio of 4.82 in contrast to the Health Care sector's average P/B ratio is 3.53
-
The current ratio is currently 13.1, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-358301000 and the average free cash flow growth rate is -316.5%
-
Revolution Medicines's revenues have an average growth rate of -19.9% with operating expenses growing at 43.4%. The company's current operating margins stand at -4207.1%